Zimmer Biomet Holdings, Inc. (ZBH)
Zimmer Biomet Holdings, Inc. is a global leader in the design, manufacture, and marketing of musculoskeletal healthcare products. The company specializes in orthopedic devices, including joint replacement implants, trauma, spine, and dental reconstruction products, serving hospitals, surgical clinics, and healthcare providers worldwide. Founded in 2015 through the merger of Zimmer Holdings and Biomet, it aims to improve patient outcomes and quality of life through innovative medical solutions.
Dividend History
Investors can expect a dividend payout of $0.24 per share, scheduled to be distributed in 41 days on October 31, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 31, 2025 | $0.24 | 2025-09-30 | 2025-09-30 |
| July 31, 2025 | $0.24 | 2025-06-26 | 2025-06-26 |
| April 30, 2025 | $0.24 | 2025-03-31 | 2025-03-31 |
| January 31, 2025 | $0.24 | 2024-12-30 | 2024-12-30 |
| October 31, 2024 | $0.24 | 2024-09-30 | 2024-09-30 |
Dividends Summary
- Zimmer Biomet Holdings, Inc. has issued 55 dividend payments over the past 13 years
- The most recent dividend was paid 51 days ago, on July 31, 2025
- The highest dividend payed out to investors during this period was $0.24 per share
- The average dividend paid during this period was $0.23 per share.
Company News
The global bone grafts and substitutes market is projected to grow from USD 3.38 billion in 2025 to USD 5.68 billion by 2034, driven by rising orthopedic disorders, trauma cases, and innovations in biomaterials and 3D printing technologies.
Zimmer Biomet reported Q2 2025 earnings with revenue of $2.077 billion, beating analyst estimates. The company saw strong growth in Sports Medicine, Extremities, and Trauma (S.E.T.) segment, raised full-year guidance, and continues to focus on robotic and digital surgery innovations.
Zimmer Biomet will acquire Monogram Technologies for $177 million, gaining advanced AI-assisted robotic knee technology with potential for fully autonomous surgical robotics, expected to enhance orthopedic surgical capabilities.
Intuitive Surgical, the leading developer of robotic surgical systems, reported strong Q4 2024 results with 18% growth in da Vinci procedure volume. However, the company expects a slowdown in procedure volume growth to 13-16% in 2025.
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
